Compare ACNB & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACNB | QTTB |
|---|---|---|
| Founded | 1857 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.4M | 44.3M |
| IPO Year | 1994 | 2018 |
| Metric | ACNB | QTTB |
|---|---|---|
| Price | $47.50 | $6.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $49.50 | $13.00 |
| AVG Volume (30 Days) | 37.4K | ★ 231.8K |
| Earning Date | 04-23-2026 | 03-10-2026 |
| Dividend Yield | ★ 3.30% | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ 3.60 | 2.42 |
| Revenue | ★ $191,821,000.00 | $53,737,000.00 |
| Revenue This Year | $13.18 | N/A |
| Revenue Next Year | $1.91 | N/A |
| P/E Ratio | $12.85 | ★ $2.71 |
| Revenue Growth | ★ 45.10 | N/A |
| 52 Week Low | $35.70 | $1.38 |
| 52 Week High | $53.89 | $7.80 |
| Indicator | ACNB | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 44.99 | 67.97 |
| Support Level | $42.84 | $1.64 |
| Resistance Level | $49.13 | $7.80 |
| Average True Range (ATR) | 1.42 | 0.80 |
| MACD | -0.10 | 0.08 |
| Stochastic Oscillator | 41.83 | 77.96 |
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.